Connor, Clark & Lunn Investment Management (CC&L)’s Revance Therapeutics, Inc. RVNC Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-145,736
| Closed | -$717K | – | 1742 |
|
|
2024
Q1 | $717K | Buy |
145,736
+113,348
| +350% | +$558K | ﹤0.01% | 995 |
|
|
2023
Q4 | $285K | Buy |
+32,388
| New | +$285K | ﹤0.01% | 1187 |
|
|
2023
Q3 | – | Sell |
-44,001
| Closed | -$1.11M | – | 1580 |
|
|
2023
Q2 | $1.11M | Sell |
44,001
-87,451
| -67% | -$2.21M | 0.01% | 763 |
|
|
2023
Q1 | $4.23M | Buy |
+131,452
| New | +$4.23M | 0.02% | 401 |
|